

Product Description

Pioneering GTPase and Oncogene Product Development since 2010


FOXN2 RABBIT PAB

Cat.#: S219783 Product Name: Anti-FOXN2 Rabbit Polyclonal Antibody Synonyms: HTLF **UNIPROT ID:** P32314 (Gene Accession - NP_002149) Background: This gene encodes a forkhead domain binding protein and may function in the transcriptional regulation of the human T-cell leukemia virus long terminal repeat. Immunogen: Synthetic peptide of human FOXN2 Applications: ELISA, WB, IHC Recommended Dilutions: IHC: 25-100;WB: 500-2000;ELISA: 5000-10000 Host Species: Rabbit Clonality: Rabbit Polyclonal Isotype: Immunogen-specific rabbit IgG Purification: Antigen affinity purification Species Reactivity: Human **Constituents:** PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol **Research Areas:** Epigenetics and Nuclear Signaling Storage & Shipping: Store at -20°C. Avoid repeated freezing and thawing




Product Description

Pioneering GTPase and Oncogene Product Development since 2010




Immunohistochemistry analysis of paraffin embedded Human breast cancer tissue using 219783(FOXN2 Antibody) at a dilution of 1/30(Nucleus).




using 219783(Anti-FOXN2 Antibody) at a dilution of with page 200 with synthetic peptide and then 1/30.

kDa	1	2
130— 95— 72—		
55—		
36 —	-	-
28 —		
17 —		
Gel: 8%SDS-PAGE, Lyse		

ate: 40 µg; Lane 1-2: K562 and Hela cell lysates; Primary antibody: 219783(FOXN2 Antibody) at dilution 1/600; Secondary antibody: HRP-conjugated Goat anti rabbit IgG at 1/5000 dilution; Exposure time: 5 minutes



In comparision with the IHC on the left, the same paraffin-embedded Human breast cancer tissue is first treated with the synthetic peptide and then with 219783(Anti-FOXN2 Antibody) at dilution 1/30.



The image on the left is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue is first tracted with with D260362(Anti-FOXN2 Antibody) at dilution 1/30.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010